Unknown

Dataset Information

0

Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.


ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Tumor hypoxia plays an active role in promoting tumor progression, malignancy, and resistance to therapy in PDAC. We present evidence that nab-paclitaxel-gemcitabine (NPG) and/or a hypoxic tumor microenvironment (TME) up-regulate heme oxygenase-1 (HO-1), providing a survival advantage for tumors. Using PDAC cells in vitro and a PDAC mouse model, we found that NPG chemotherapy up-regulated expression of HO-1 in PDAC cells and increased its nuclear translocation. Inhibition of HO-1 with ZnPP and SnPP sensitized PDAC cells to NPG-induced cytotoxicity (p < 0.05) and increased apoptosis (p < 0.05). Additionally, HO-1 expression was increased in gemcitabine-resistant PDAC cells (p < 0.05), and HO-1 inhibition increased GEM-resistant PDAC sensitivity to NPG (p < 0.05). NPG combined with HO-1 inhibitor inhibited tumor size in an orthotopic model. In parallel, HO-1 inhibition abrogated the influx of macrophages and FoxP3+ cells, while increasing the proportion of CD8+ infiltration in the pancreatic tumors. These effects were mediated primarily by reducing expression of the immunosuppressive cytokine IL-10.

SUBMITTER: Ahmad IM 

PROVIDER: S-EPMC8125955 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.

Ahmad Iman M IM   Dafferner Alicia J AJ   O'Connell Kelly A KA   Mehla Kamiya K   Britigan Bradley E BE   Hollingsworth Michael A MA   Abdalla Maher Y MY  

Cancers 20210508 9


Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Tumor hypoxia plays an active role in promoting tumor progression, malignancy, and resistance to therapy in PDAC. We present evidence that nab-paclitaxel-gemcitabine (NPG) and/or a hypoxic tumor microenvironment (TME) up-regulate heme oxygenase-1 (HO-1), providing a survival advantage for tumors. Using PDAC cells in vitro and a PDAC mouse model, we found that NPG chemotherapy up-regulated expression of HO-  ...[more]

Similar Datasets

| S-EPMC9178436 | biostudies-literature
| S-EPMC10284354 | biostudies-literature
| S-EPMC10177033 | biostudies-literature
| S-EPMC10618946 | biostudies-literature
| S-EPMC10026489 | biostudies-literature
| S-EPMC7364337 | biostudies-literature
| S-EPMC8133644 | biostudies-literature
| S-EPMC7073299 | biostudies-literature
| S-EPMC10082313 | biostudies-literature
2023-07-05 | PXD042267 | Pride